RUO peptide website compliance is usually treated as a wording question: which disclaimer to use and where to put it. The FDA warning letters sent to peptide sellers in 2026 show that the question is wider. In each one the agency acknowledged the research-use-only (RUO) label, then quoted the seller’s own website to show what the products were intended for. This guide is for owners and marketers of RUO peptide stores. It summarises what those letters cited, sets out what ad platforms and payment processors read on the same pages, and ends with a 25-point site audit. It is marketing and policy information, not legal advice.
- The website was the evidence. All six 2026 letters we read rest on text and products found on the seller’s own site.
- The disclaimer was noted and set aside. Each letter records the research-use wording, then says the site shows the products are intended as drugs for people.
- Research framing did not protect a claim. Lines built on “studied for” or “research shows” were quoted as evidence of intended use.
- Supplies counted. Bacteriostatic water sold next to peptides was cited in five of the six letters, and charged as a drug in four.
- Some things were not cited. None of the six letters quotes a testimonial, an image or a social post. US and UK rules still reach them.
- Platforms and processors read the same pages and apply their own rules, whatever the label says.
- An audit makes the site match the business. It does not make a business selling for personal use compliant.
- Why the website is the evidence
- What the 2026 FDA warning letters cited
- Why a disclaimer alone is not enough
- Product copy, comparison pages and blog content
- Testimonials, reviews, images and social links
- Dosing language, calculators and bundled supplies
- What ad platforms and payment processors look at
- A short UK note: ASA and MHRA
- The 25-point site audit
- FAQ
- Sources
1. Why the website is the evidence
Under US law, whether a product is a drug depends on its intended use, not on what the label calls it. The regulation the 2026 letters cite is 21 CFR 201.128. It says intended use means the objective intent of the people responsible for the product. That intent can be shown by what they say, by the design or composition of the product, and by the circumstances in which it is distributed. The regulation gives labeling claims, advertising matter, and oral or written statements as examples.
A website is all of those at once. Product pages, comparison articles, the navigation menu, the items in the catalogue and the tools on the site are statements made by the seller. A reviewer does not need inside information. They need a browser and a date.
That is how the 2026 letters were built. Each one says the FDA reviewed the firm’s website in a stated month, lists product page URLs, and quotes text from them. None of the six relies on an inspection, a test purchase or a lab result.
The same pages are read by Google’s ad and Merchant Center review, by your payment processor’s risk team, and, if you sell to the UK, by the MHRA and the ASA. Their rules differ, but they share one feature: none of them accepts the seller’s label as the last word.
2. What the 2026 FDA warning letters cited
We read six warning letters that the FDA’s Center for Drug Evaluation and Research sent to peptide sellers in 2026. Four are dated 24 August 2026, which we confirmed on fda.gov. Each of those four says the firm’s website was reviewed in July 2026. The other two are dated 31 March and 17 June 2026. All six came from the Office of Unapproved Drugs and Labeling Compliance. There may be other 2026 letters we have not read.
The charge is the same in each. The products are drugs because of their intended use, they are new drugs without an approved application, and introducing them into interstate commerce violates the Federal Food, Drug, and Cosmetic Act. Each firm was asked to reply within fifteen business or working days, and warned that failure to correct violations could lead to legal action, including seizure and injunction.
| Letter | Date | Site evidence the FDA cited, in our words |
|---|---|---|
| Gram Peptides | 31 March 2026 | Product-page text on appetite, body weight, glucose and lipids. Bacteriostatic water sold alongside peptides that need reconstitution, and charged as a drug. |
| Wholesale Peptide | 17 June 2026 | Product-page text naming prostate conditions, with benefits introduced by “research shows”. Text on testosterone production and cancer research. |
| Peak Performance Peptides | 24 August 2026 | Product-page lines framed as “studied for” or “investigated for” effects on glycemic control, appetite and fat distribution. Bacteriostatic water charged as a drug. |
| Peptide Partners LLC | 24 August 2026 | Product-page summaries of studies suggesting benefits for bone, kidney and brain health. A “reconstitution solution” charged as a drug. |
| Royal Peptides LLC | 24 August 2026 | Comparison pages with benefit lists and clinical results, including the phrase “Once-weekly injection for convenience”. A mixed multi-pack kit and a blend. Bacteriostatic water marketed beside a peptide guide and a peptide calculator. |
| TXP Innovations LLC dba Tex Peptides | 24 August 2026 | Product-page text on supporting weight loss and managing type 2 diabetes and obesity. Bacteriostatic water marketed as a solvent for the site’s products, and charged as a drug. |
The patterns across the six letters
- Product-page claims are the core. Every letter quotes product or comparison pages. Statements about weight, appetite, blood sugar, named diseases or body function are treated as evidence of intended use.
- Research phrasing did not change the reading. Several of the quoted lines are written as descriptions of studies. The FDA quoted them anyway.
- Reconstitution supplies are evidence. Five letters cite bacteriostatic water or a reconstitution solution sold next to the peptides. Four charge the water itself as an unapproved drug, reasoning that the pairing shows it is meant for injection.
- Tools and bundles appear. One letter cites a peptide guide and calculator, a mixed kit and a blend.
- The catalogue repeats. Semaglutide, retatrutide, tesamorelin, PT-141 and SS-31 are named in all four August letters, and tirzepatide in three.
- The disclaimer is acknowledged in a footnote. Section 3 covers this.
None of the six letters quotes a customer testimonial or review, describes an image, or cites a social media account, hashtag, email or discount code. None mentions syringes. The reviews covered websites. This matters for accuracy: articles that say the FDA “flagged testimonials and Instagram” in these letters are not describing these letters. Sections 5 and 8 explain why those areas still belong in an audit.
3. Why a disclaimer alone is not enough
Every one of the six letters records that the firm’s labeling marketed the products for research use only and not for human consumption, or close variants of that wording. Each then says that the evidence from the website establishes the products are intended to be drugs for human use. The disclaimers were present and the FDA saw them. They did not decide the outcome.
The FDA has said the same thing to consumers. Its page on unapproved GLP-1 drugs, updated on 1 October 2026, says the agency has warned companies selling certain products it describes as “falsely labeled” for research purposes or as not for human consumption, and that these were sold directly to consumers for human use with dosing instructions.
The reasoning follows from section 1. A disclaimer is one statement. Intended use is judged on all the statements and circumstances together. If a footer says “for laboratory research only” and the product page above it describes appetite and body weight, the two conflict, and the reviewer goes with the weight of the page.
A research-use statement is worth having when it is true. It tells a genuine research buyer what the product is and is not, and it should appear on the product page, the label, the checkout and the terms of sale. It works as a summary of how the business operates. It does not work as a correction to the rest of the site.
The same logic limits what an audit can do. Removing claims from a site that still sells to people buying for personal use changes the wording and leaves the circumstances of distribution untouched, and the regulation counts those circumstances too. This guide is about making a site consistent with a real research-supply business. We do not help disguise human-use sales, and no wording would do that reliably anyway.
4. Product copy, comparison pages and blog content
Product pages
The quoted text in the letters has a common shape: it tells the reader what the compound does in a body, or which condition it relates to. A research supplier’s page has a different job. It identifies the material and documents its quality. The table shows the difference by area.
| Area of the page | Reads as intended for human use | Consistent with a research-supply business |
|---|---|---|
| Product name | Names built around a drug class or an outcome | The compound’s accurate chemical or common name, matching the label and certificate of analysis |
| Description | Effects on weight, appetite, sleep, recovery, ageing or a named condition | Identity, sequence or formula, molecular weight, quantity, form, stated purity |
| Study summaries | Benefit lists drawn from trials, whatever phrase introduces them | None on the sales page. Analytical data for the batch instead |
| Usage information | Amounts, schedules, routes, or mixing steps for use | Storage and handling as supplied, and safety data sheet information |
| Documentation | A purity badge with nothing behind it | A batch-specific certificate of analysis and the test method |
| Research-use statement | A footer line that contradicts the page above it | A statement on the page, label and checkout that matches everything else |
Two details from the letters are worth applying directly. First, phrases such as “studied for” and “research shows” did not turn a benefit statement into something else. Second, one letter quoted text under a heading about advanced research use that listed anti-ageing and neuroprotection. A research heading over an outcome list is still an outcome list.
Comparison pages and blog content
One August letter cites two comparison pages by URL. One address contains a weight-loss phrase, and the quoted text includes benefit lists and trial results. They sit outside the shop section, like blog posts. The lesson is that everything on the domain counts, not just product pages.
For a blog on an RUO store, our standard is:
- No articles that compare compounds by outcome for a person, or that explain how to choose between them.
- No articles on protocols, cycles, schedules or results.
- No outcome or condition words in URLs, page titles or meta descriptions. They are statements too.
- Topics that fit the business: analytical methods, how to read a certificate of analysis, storage and stability, shipping and documentation.
- Old posts get the same review as new ones. An archived article is still published.
5. Testimonials, reviews, images and social links
These areas were not cited in the six letters. They are still statements or circumstances connected to the seller, so they fall inside the intended-use regulation, and other reviewers name them directly. The MHRA’s guidance, covered in section 8, lists websites, social media and customer reviews among the things it looks at.
Testimonials and reviews
A review that describes a personal result is a human-use statement displayed on your product page. You did not write it, but you chose to publish it. For a research supplier, reviews that make sense are about the things a lab buyer can judge: documentation, packaging, delivery time and service. If your review tool imports text automatically, moderate it against a written rule, and apply the rule to every review, not only to the ones that look risky. Do not write, buy or edit reviews.
Images
Images make claims without words. Body or before-and-after imagery, lifestyle photography, and pictures of injection equipment or a product being prepared for use all say who the product is for. An accurate photograph of the item as sold, with its real label, says what it is. Check alt text and file names as well, because they are published text.
Social links
A social icon in the footer joins that account to the site. If the account, its bio, its hashtags or its reposts talk about personal use or results, a reviewer following the link will read them as the seller’s statements. The same applies to affiliates and anyone paid to promote the store: what they say for you is said on your behalf. Link only to accounts you would be content to have read alongside your product pages.
6. Dosing language, calculators and bundled supplies
This is the area where the 2026 letters are most specific.
- Bacteriostatic water. Five of the six letters cite it. Four go further and charge the water as an unapproved drug, on the reasoning that selling it to reconstitute the site’s peptides shows it is intended for injection.
- Calculators and guides. One letter notes the water was marketed alongside a “peptide guide” and a “peptide calculator”.
- Kits and blends. The same letter cites a mixed multi-pack of two compounds and a pre-combined blend.
- Dosing language. The FDA’s consumer page describes these products as sold with dosing instructions. One letter quotes a line about weekly injection.
Read together, these describe what regulators call the circumstances of distribution. A catalogue of single-use retail vials, a mixing liquid, a tool that converts amounts, and a multi-pack is a picture of a consumer product, whatever each page says. The letters also explain why the FDA cares: they note that injectable products are delivered directly into the body and bypass its natural defences.
An RUO site should carry no dosing, administration or reconstitution-for-use content, no calculators, and no bundles assembled around personal use. Whether to sell ancillary supplies at all is a business and legal decision for the owner and their counsel. We will not suggest moving these items to a second domain or a hidden page. The letters show how such supplies are read, and relocating them does not change what they are sold for.
7. What ad platforms and payment processors look at
Google Ads and Merchant Center
Google’s Healthcare and medicines policy for ads has an Unapproved substances section that applies “regardless of any claims of legality”. Its list includes non-government-approved products marketed as safe or effective for a disease, products that imply they work as well as prescription drugs, products with names confusingly similar to an unapproved pharmaceutical or controlled substance, and products that have been subject to government or regulatory action or warning. Merchant Center’s Healthcare and medicines policy uses the same wording for product listings.
Three practical points follow:
- The landing page is reviewed, not only the ad. The policy refers to landing pages and websites throughout. A clean ad pointing at a page with outcome claims is a page problem.
- A warning letter is itself a policy trigger. The regulatory-action bullet means that compounds named in FDA letters carry extra risk in ads and feeds.
- Review must see what buyers see. Google’s Abusing the ad network policy does not allow ads, content or destinations that try to trick or circumvent its review processes. Showing reviewers a different page from the one customers get is a violation in its own right.
Google’s Misrepresentation policy also covers unreliable claims, meaning inaccurate claims or ones that present an improbable result as likely. For the campaign side, see our guides to Google Ads for peptides and Google Shopping for peptides. If your account already has a suspension, start with Merchant Center recovery. Earlier guides in this series cover appealing a Google Ads suspension and setting up Performance Max with policy-safe creative.
Payment processors
Processors publish their own lists, and they read your site when you apply and again when they review the account. Two public examples:
- Stripe’s prohibited and restricted businesses list prohibits “Incorrectly labeled research chemicals”, along with pseudo-pharmaceuticals that are not safe or make harmful claims. It restricts card-not-present sales of pharmaceuticals and prescription-only products.
- PayPal’s Acceptable Use Policy prohibits transactions involving products that present a risk to consumer safety, and requires pre-approval to sell products that need a prescription.
Neither page names peptides. Both are written broadly enough that the outcome depends on what an underwriter concludes from your website and your description of the business. That description must be accurate. Telling a processor you sell something else is misrepresentation and puts funds at risk. Our peptide payment processing guide covers how to approach this openly.
Emails are written statements by the seller, and they get forwarded. Hold campaigns, flows and subject lines to the same standard as product pages. Our peptide email marketing guide covers this within RUO framing.
8. A short UK note: ASA and MHRA
If you sell to UK customers or run a UK company, two bodies matter.
The MHRA decides what is a medicine. The Human Medicines Regulations 2012 define a medicinal product in two ways: by presentation, as something presented as preventing or treating disease, and by function, as something that may be administered to modify a physiological function through pharmacological, immunological or metabolic action. The MHRA’s borderline products guidance says it looks at explicit and implicit claims, the properties of the ingredients, how consumers would use the product, and how it is presented, including websites, social media and customer reviews. The page does not say that a disclaimer settles the question. Regulation 279 prohibits advertising a medicinal product that has no marketing authorisation.
The ASA regulates advertising. Section 12 of the CAP Code allows medicinal claims only for licensed products and bars advertising prescription-only medicines to the public. The Code’s scope covers a company’s own website and, for UK-registered marketers, its non-paid social media. CAP’s advice on prescription-only medicines, dated 30 September 2026, says almost any reference to such a medicine is likely to be treated as promoting it, that landing pages count, and that references in posts, images and hashtags can count too. Several catalogue names in the US letters are prescription-only medicines in the UK, so product naming is an advertising question there.
9. The 25-point site audit
The infographic groups the audit by area. Each point is a question to answer with yes or no about your live site.
A. Product pages
B. Blog and site content
C. Reviews and images
D. Catalogue and supplies
E. Off-site and channels
F. Statements and operations
How to run it
- Read the primary sources first. Open two or three of the FDA letters linked above and read the quoted site text yourself.
- List every published URL. Use your sitemap and a crawl. Include blog posts, category pages, PDFs, old landing pages and anything not linked from the menu.
- Go through the 25 points page by page. Record yes or no, with the URL, for each one.
- Search the site for outcome and use words. Search for condition names, body-function words and use verbs. Check page titles, meta descriptions and alt text as well as body copy.
- Check what is connected to the site. Social profiles, review widgets, email templates, affiliate pages and any marketplace listings.
- Fix the page, not its visibility. Correct or remove the content for all visitors. Do not hide it from reviewers, and do not move it to another domain.
- Align the channels. Update the product feed, ad copy and email flows so they match the corrected pages.
- Take the legal questions to a lawyer. Catalogue decisions, supplies, terms of sale and any regulator correspondence need an attorney who works in FDA or UK medicines law.
- Log and repeat. Keep a dated record of each change. Re-run the audit every quarter and after any redesign, plugin change or new product launch.
10. FAQ
What is RUO peptide website compliance?
It means the whole website is consistent with a business that supplies materials for laboratory research. Product copy, blog content, reviews, images, supplies and linked accounts are all read as evidence of intended use, so compliance covers all of them, not just the disclaimer.
Is a “research use only” disclaimer enough to protect a peptide site?
No. Each of the six 2026 FDA warning letters we read notes the seller’s research-use labeling, then says website evidence shows the products are intended as drugs for human use. A disclaimer is one statement among many and is weighed with the rest of the site.
What did the August 2026 FDA warning letters to peptide sellers cite?
The four letters dated 24 August 2026 cite product-page and comparison-page text about effects on the body, and bacteriostatic water or a reconstitution solution sold alongside the peptides. One also cites a peptide guide, a calculator, a mixed kit and a blend.
Did the FDA letters cite testimonials or social media?
Not in the six letters we read. None quotes a testimonial, describes an image or cites a social account. Those areas can still count as evidence of intended use under 21 CFR 201.128, and the MHRA’s UK guidance lists social media and customer reviews by name.
Can we keep health claims if we write “studies suggest” in front of them?
The letters indicate not. Several of the lines the FDA quoted were framed as “studied for”, “investigated for” or “research shows”. The agency treated them as evidence of intended use regardless of the framing.
Should an RUO store sell bacteriostatic water?
That is a decision to take with legal advice. Five of the six letters cite it as evidence, and four charge it as an unapproved drug because it was sold to reconstitute the site’s peptides. Moving it to another domain does not change that reading.
Do Google and payment processors accept the RUO label?
Not on its own. Google’s Unapproved substances policy applies regardless of any claims of legality, and it reviews landing pages. Stripe prohibits incorrectly labeled research chemicals. Both judge what the site shows.
Does passing this audit mean the site is legal?
No. The audit checks that the site describes a research-supply business accurately and consistently. It is marketing and policy information, not legal advice, and it cannot make a business that sells for personal use compliant.
Have your site read the way a reviewer reads it
Peptide Marketing works only with research-use-only peptide brands. We will go through your site against the 25 points, show you which pages a regulator, ad platform or processor would quote, and tell you plainly what to change first. We do not cloak pages, disguise product names or hide content from reviewers.
Prefer email? Write to hello@peptidemarketing.info.
Sources
- FDA warning letters dated 24 August 2026: Peak Performance Peptides, Peptide Partners LLC, Royal Peptides LLC, TXP Innovations LLC dba Tex Peptides
- FDA warning letters: Wholesale Peptide, 17 June 2026 and Gram Peptides, 31 March 2026
- FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
- 21 CFR 201.128, Meaning of “intended uses”, as published by Cornell Legal Information Institute
- Google Ads policy: Healthcare and medicines, Misrepresentation and Abusing the ad network
- Google Merchant Center Help: Healthcare and medicines
- Stripe: Prohibited and Restricted Businesses. PayPal: Acceptable Use Policy
- UK legislation: Human Medicines Regulations 2012, regulation 2 and regulation 279
- MHRA: Borderline products: how to tell if your product is a medicine
- ASA and CAP: CAP Code section 12, Scope of the Code and Healthcare: Prescription-only medicine
This guide is marketing and platform-policy information for businesses selling research-use-only products. It is not legal or regulatory advice. Sources were read in November 2026. Laws, letters and policies change, so check the linked pages and take advice from a qualified attorney before you act.
Leave a Reply